Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients

Abstract

Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics. The authors identify differences between responders and nonresponders and recommend controlled trials.